Home \ Ophthalmology \ Current Strategies for Neuroprotection in Glaucoma

Actual strategies for neuroprotement in glaucoma

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

01:15
The purpose of the treatment of glaucoma
02:29
The need for neuroprotement
03:10
Approaches to neuroprotection
04:06
The use of retinolamine
06:11
Laser transconde -junkoagulation method
10:10
The method of indirect retinoprotection
12:00
Study of Mexidol® in patients with I-III soup
13:20
The maximum positive effect during a dosage of 300 mg per day
15:26
The effectiveness of the drug Mexidol® at the III stage of the disease
16:28
Course therapy Mexidol® and Mexidol® Forte
17:32
Clinical recommendations

Egorov Evgeniy Alekseevich – Doctor of Medical Sciences, Professor, President of the Russian Glaucoma Society, Head. Department of Ophthalmology named after. Academician A.P. Nesterov RNRMU named after. N.I. Pirogov

Announcement:

The primary goal of glaucoma treatment is to preserve visual function and quality of life at a reasonable cost. Neuroprotection is a crucial aspect of maintaining visual function in patients with glaucoma. Studies have demonstrated the efficacy and safety of Mexidol® in patients with primary open-angle glaucoma stages I-III.

All videos Next video

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

01:15
The purpose of the treatment of glaucoma
02:29
The need for neuroprotement
03:10
Approaches to neuroprotection
04:06
The use of retinolamine
06:11
Laser transconde -junkoagulation method
10:10
The method of indirect retinoprotection
12:00
Study of Mexidol® in patients with I-III soup
13:20
The maximum positive effect during a dosage of 300 mg per day
15:26
The effectiveness of the drug Mexidol® at the III stage of the disease
16:28
Course therapy Mexidol® and Mexidol® Forte
17:32
Clinical recommendations

Block of articles on this topic

The effect of antioxidant therapy on some pathogenetic factors of primary open -angle glaucoma

Authors:
T.N. MALISHEVSKAYA¹, Yu.E. FILIPPOVA²

¹Federal State Budgetary Institution "Helmholtz National Medical Research Center for Eye Diseases" of the Ministry of Health of the Russian Federation, Moscow, Russia;
²State Autonomous Healthcare Institution of the Tyumen Region "Regional Ophthalmological Dispensary", Tyumen, Russia

Mexidol in the complex treatment of glaucoma

Author:
E.A. EGOROV, N.G. DAVYDOVA, I.A. ROMANENKO, N.D. NOVIKOVA

RNIMU named after N.I. Pirogov, GB of GB named after Helmholtz, Moscow

The possibilities and results of the use of antioxidant therapy in ophthalmological practice

Authors:
A.B. MOVSISYAN^1,2, Zh.G. OGANEZOVA^2,3, E.A. EGOROV²

¹Hospital for War Veterans No. 2 of the Moscow Health Department, Moscow, Russia;
²Pirogov Russian National Research Medical University, Moscow, Russia;
³Bochkov Medical Genetic Research Center, Moscow, Russia

The experience of neuroprotective therapy of primary open -angle glaucoma based on the use of various forms of Mexidol

Authors:
E.S. LEONOVA^1,2, S.V. POLYAKOV^1,2, M.A. POZDNYAKOVA², E.P. YARYGINA³, S.O. SEMISYNOV²

^1.NGO "Road Clinical Hospital at Gorky Station of JSC "Russian Railways", Inter-Road Ophthalmology Center
^2.State Budgetary Educational Institution of Higher Professional Education "Nizhny Novgorod State Medical Academy"
^3.State Budgetary Healthcare Institution of the Nizhny Novgorod Region "City Hospital No. 35", City Glaucoma Center

The use of Mexidol in the treatment of primary open -angle glaucoma

Authors:
I.A. LOSKUTOV, O.M. ANDRYUKHINA, A.A. KOVRIZHKINA

Moscow Regional Research Clinical Institute. M.F. Vladimir

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com